Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
June 13, 2018

New screening guidelines for colorectal cancer aim to reduce mortality and morbidity

The American Cancer Society recently published new guidelines for colorectal cancer (CRC) screening, recommending that screening begin at age 45 rather than 50. This change is intended to expand routine screening to more than 20 million Americans, with an overarching aim of reducing colorectal cancer mortality and morbidity.

By GlobalData Healthcare

The American Cancer Society recently published new guidelines for colorectal cancer (CRC) screening, recommending that screening begin at age 45 rather than 50. This change is intended to expand routine screening to more than 20 million Americans, with an overarching aim of reducing colorectal cancer mortality and morbidity. Figure 1 presents the diagnosed incident cases of colorectal cancer in the US in 2016.

Colorectal cancer originates in either the colon or the rectum and is one of the most common types of cancer in the US, with more than 140,000 estimated incident cases in 2018. Men and women over 45 years old make up the majority of cancer cases and are considered those at highest risk for developing the disease.

CRC is a high-mortality cancer, with symptoms including blood in stool, stomach pains, aches or cramps that do not go away, weight loss, and a persistent change in bowel habit. The tests used to detect and diagnose CRC are physical rectal examination, fecal occult blood test, and colonoscopy. CRC screening programs aim to identify and remove pre-cancerous polyps in the colon or rectum. The removal of pre-cancerous polyps has been shown to reduce mortality and morbidity. With these changes in recommended screening ages, it is likely that a further reduction in mortality can be achieved; however, this may come with an apparent increase in the number of cases in ages 45–49 years old as more people undergo screening sooner.

Related Reports

  • GlobalData (2016). EpiCast Report: Colorectal Cancer – Epidemiology Forecast to 2025, December 2016, GDHCER141-16.
  • GlobalData (2016). EpiCast Model: Colorectal Cancer – Epidemiology Forecast to 2025, December 2016, GDHCEM141-16.

For more insight and data, visit the GlobalData Report Store – Medical Device Network is part of GlobalData Plc.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU